Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2017 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome.
Vivarelli M, Colucci M, Algeri M, Zotta F, Emma F, L'Erario I, Busutti M, Rota S, Capelli C, Introna M, Todeschini M, Casiraghi F, Perna A, Peracchi T, De Salvo A, Rubis N, Locatelli F, Remuzzi G, Ruggenenti P. Vivarelli M, et al. Among authors: de salvo a. JCI Insight. 2023 Sep 22;8(18):e169424. doi: 10.1172/jci.insight.169424. JCI Insight. 2023. PMID: 37561590 Free PMC article. Clinical Trial.
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
Miglietta F, Dieci MV, Giarratano T, Torri V, Giuliano M, Zustovich F, Mion M, Tondini CA, De Rossi C, Bria E, Franchi M, Merlini L, Giannatiempo R, Russo D, Fotia V, Poletti P, Caremoli ER, Arpino MG, De Salvo GL, Zambelli A, Guarneri V. Miglietta F, et al. Among authors: de salvo gl. Eur J Cancer. 2023 Dec;195:113399. doi: 10.1016/j.ejca.2023.113399. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37950941 Free article.
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G. Caccese M, et al. Among authors: de salvo gl. ESMO Open. 2024 Mar 15;9(4):102943. doi: 10.1016/j.esmoop.2024.102943. Online ahead of print. ESMO Open. 2024. PMID: 38492275 Free PMC article.